Mad Money's Jim Cramer reflects on CNBC's evolution over the past 25 years.» Read More
U.S. investment bank Merrill Lynch does not plan to raise further capital as it has already raised more than it has lost, Chief Executive John Thain said on Tuesday.
The Star-Ledger of New Jersey this weekend did a story that I think provides the best insight and backstory about what happened last week at the highest levels of Schering-Plough.CEO Fred Hassan was in Miami when doctors dropped the bomb on Vytorin and Zetia at the American College of Cardiology meeting.
CEO Fred Hassan updates investors on his company's plans to rebound from the Vytorin debacle.
JPMorgan Chase, which is taking over rival investment bankBear Stearns, will dominate the management ranks of the combined company's investment banking and trading businesses, according to an internal memo.
When you're stressed, do you hit the bar or hit the gym? Do you drink whiskey or wheatgrass? Lululemon Athletica's incoming CEO Christine Day says that one strategic advantage of the high-priced yoga wear line is that during an economic downturn, people choose things to relieve that stress--like working out.
After the closing bell yesterday, Amgen put out a press release announcing that phase 3 pivotal data are being published in a scientific/medical journal about its most important drug development pipeline product--an osteoporosis drug known as D-mab. (Whenever you see the letters mab at the end of the scientific name for a drug it means it's a monoclonal antibody).
Forget ethanol – this company’s got an alternative for the alternative.
Cramer went right to the source to find out. Let the CEO explain.
Given investor reaction to the Vytorin/Zetia news yesterday, you might draw the conclusion the huge cholesterol drug franchise might be doomed. Sure, analysts say, prescriptions and sales are gonna go down some more, but they're not going to zero.
"We stand behind our product," Fred Hassan says. But does Cramer?
The CEO of the engineering company tells Cramer what he's doing to dominate the oil and gas market.
When I heard a soundbite with Sen. Hillary Clinton on CNBC's "Kudlow & Company" last night, it reminded me to check and see if the Center for Responsive Politics had updated its monthly campaign contribution data.
A U.S. federal judge has temporarily blocked a former senior Bear Stearns executive from jumping to Morgan Stanley and recruiting clients and colleagues to follow him.
Bank of America said it has agreed to pay $28 million to Countrywide Financial Chief Operating Officer David Sambol to induce him to run the merged companies' consumer mortgage operations.
The Columbia Journalism Review, the pre-eminent publication and authority on what we in the business refer to as "The Big J"--as in Journalism--is calling out CBS' "60 Minutes" in an article just posted on the web with the somewhat explosive headline, "60 Minutes Blows Biovail Story."
But a global economic boom will keep at least some prices up.
While the rest of the sector was going bankrupt, this company thrived. No wonder it's Cramer's favorite in the group.
Vanguard founder and former CEO John Bogle told CNBC that he expects the stock market's meager returns to continue for some time. "Be mentally prepared for some pretty slovenly going--some subdued returns--for quite a few years," Bogle said.
This morning, Bear Stearns biotech analyst Mark Schoenebaum and a couple of members of his research team hosted a conference call with a 50-page PowerPoint about Amgen. The purpose was to drill down into the looming court decision over whether Roche will be able to launch a competing anemia drug in the U.S. for kidney dialysis patients.
Big pharma CEOs might wanna watch their backs because there could be a burgeoning power struggle in the C-suite. Ernst & Young, which has a long history of doing comprehensive reports on the pharmaceutical and biotech industries, is out with a new one today declaring that it's big pharma Chief Financial Officers who have all the mojo these days.